April 21, 2026

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

Conexiant

April 20, 2026

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Conexiant

April 16, 2026

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

Conexiant

April 16, 2026

When ‘Family Planning’ Shifts Meaning

A program built on prevention now tilts toward population goals, testing the balance between public health and personal choice.

KFF Health News

April 16, 2026

When ‘Family Planning’ Shifts Meaning

A program built on prevention now tilts toward population goals, testing the balance between public health and personal choice.

KFF Health News

April 09, 2026

Marriage as a Marker of Cancer Risk?

Never-married adults show markedly higher cancer incidence. A large population study asks why marital status remains a footnote in risk frameworks.

Conexiant

April 07, 2026

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant